Tumor uptake of the RGD dimeric probe99mTc-G3-2P 4-RGD2 is correlated with integrin αv/β 3 expressed on both tumor cells and neovasculature

Bioconjugate Chemistry

Volumn 21, Issue 3, 2010, Pages 548-555

  Liu, Zhaofei ^a   Jia, Bing ^a   Shi, Jiyun ^a   Jin, Xiaona ^b   Zhao, Huiyun ^a   Li, Fang ^b   Liu, Shuang ^c   Wang, Fan ^a  

^a PEKING UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROBES; TUMORS;

ARG GLY ASPS; CO-LIGANDS; EXPRESSION LEVELS; IN-VIVO; INTEGRINS; NEOVASCULATURE; NON-INVASIVELY MONITORING; TUMOR ANGIOGENESIS; TUMOR UPTAKE; TUMOUR CELLS;

BINDING ENERGY;

ARGINYLGLYCYLASPARTIC ACID; SULFONIC ACID DERIVATIVE; TECHNETIUM 99M; TRIPHENYLPHOSPHINE; VITRONECTIN RECEPTOR; ARGINYL-GLYCYL-ASPARTIC ACID; CYCLOPEPTIDE; FLUORESCENT DYE; OLIGOPEPTIDE; TECHNETIUM 99M HYNIC-GLY3-E(PEG4-C(RGDFK)); TECHNETIUM COMPLEX;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DISTRIBUTION; DRUG UPTAKE; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; TUMOR CELL; TUMOR VASCULARIZATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; DIMERIZATION; HT 29 CELL LINE; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); TISSUE DISTRIBUTION; TUMOR CELL CULTURE; VASCULARIZATION;

MURINAE; MUS MUSCULUS;

ANIMALS; DIMERIZATION; FEMALE; FLUORESCENT DYES; HT29 CELLS; HUMANS; INTEGRIN ALPHAVBETA3; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; OLIGOPEPTIDES; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES, CYCLIC; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 77949845083     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc900547d     Document Type: Article

References (37)

1. Bergers, G., and Benjamin, L. E. (2003) Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 3, 401-410.
2. 3 for angiogenesis. Science 264, 569-571.
3. Hood, J. D., and Cheresh, D. A. (2002) Role of integrins in cell invasion and migration. Nat. Rev. Cancer 2, 91-100.
4. 3 antagonism. Anticancer Agents Med. Chem. 6, 407-428.
5. vβ 3-targeted cancer therapy. Drug Dev, Res- 69, 329-339.
6. 3 expression. Front. Biosci. 14, 887-899.
7. 3 expression. Cancer Metastasis Rev. 27, 631-644.
8. 3 targeted radiotracers for tumor imaging. Mol. Pharm. 3, 472-487.
9. 3 expression. Mini Rev. Med. Chem. 6, 227-234.
10. 18F]galacto-RGD positron, emission tomography. Neuro Oncol. 11, 861-870.
11. Kenny, L. M., Coombes, R. C., Oulie, I., Contractor, K. B., Miller, M., Spinks, T. J., McParland, B., Cohen, P. S., Hui, A. M., Palmieri, C., Osman, S., Glaser, M., Turton, D., Al-Nahhas, A., and Aboagye, E. O. (2008) Phase I trial, of the positron-emitting Arg-Gly-Asp (RGD) peptide radioligand 18F-AH111585 in breast cancer patients. J. Nucl. Med. 49, 879-886.
12. 3 expression in primary and metastatic human breast cancer as shown by F-Galacto-RGD PET. J. Nucl. Med. 49, 255-259.
13. 3 expression on the neovasculature in patients with squamous cell carcinoma of the head and neck. Clin. Cancer Res. 13, 6610-6616.
14. 18F-galacto-RGD and 18F-FDG. J. Nucl. Med. 49, 22-29.
15. 4 linkers. Eur. J. Nucl. Med. Mol. lmaging 36, 1296-1307.
16. 3PET imaging.Eur.J.Nucl.Med.Mol.Imaging.36,947-957.
17. Shi, J., Wang, L., Kim, Y. S., Zhai, S., Liu, Z., Chen, X., and Liu, S. (2008) Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers. J. Med, Chem. 51, 7980-7990.
18. 4 linkers. Mol. Pharm. 6, 231245.
19. Hynes, R. O. (1992) Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
20. 3 integrin in human melanoma cell invasion. Proc. Natl. Acad. Sci. U.S.A. 89, 1557-1561.
21. 3 expression, with, nearinfrared fluorescent RGD dimer with tetra(ethylene glycol) linkers. Mol. Imaging 9, 21-29.
22. Harris, T. D., Sworin, M., Williams, N., Rajopadhye, M., Damphousse, P. R., Glowacka, D., Poirier, M. J., and Yu, K. (1999) Synthesis of stable hydrazones of a hydrazinonicotinylmodified peptide for the preparation of 99mTc-labeled radiopharmaceuticals. Bioconiugate Chem. 10, 808-814.
23. 3 expression. Bioconjugate Chem. 17. 1069-1076.
24. Liu, Z., Yan, Y., Chin, F. T., Wang, F., and Chen, X. (2009) Dual integrin and gastrin-releasing peptide receptor targeted tumor imaging using 18F-labeled PEGylated RGD-bombesin heterodimer 18F-FB-PEG3-Glu-RGD-BBN. J. Med, Chem- 52, 425-432.
25. 64Cu-Labeled RGD-Bombesin Heterodimer. J. Nucl. Med. 50, 1168-1177.
26. Liu, Z., Yu, Z., He, W., Ma, S., Sun, L., and Wang, F. (2009) In-vitro internalization and in-vivo tumor uptake of anti-EGFR monoclonal antibody LA22 in A549 lung cancer cells and animal model, Cancer. Biother. Radiopharm. 24, 15-24.
27. 3 with 111 In-labeled Abegrin™ in nude mouse models. Mol. Imaging Biol, in press.
28. 3-targeted radioimmunotherapy of glioblastoma multiforme. Clin. Cancer Res. 14, 7330-7339.
29. 3. Cancer Res. 66, 9673-9681.
30. Liu, Z., Niu, G., Wang, F., and Chen, X. (2009) 68Ga-labeled NOTA-RGD-BBN peptide for dual integrin and GRPR-targeted tumor imaging. Eur. J. Nucl. Med. Mol. Imaging 36, 1483-1494.
31. 3-targeted radiotracers: maximizing binding affinity via bivalency. Bioconjugate Chem. 20, 2199-2213.
32. Cai, W., Rao, J., Gambhir, S. S., and Chen, X. (2006) How molecular imaging is speeding up antiangiogenic drug development. Mol. Cancer Ther. 5, 2624-2633.
33. Willmann, J. K., van Bruggen, N., Dinkelborg, L. M., and Gambhir, S. S. (2008) Molecular imaging in drug development. Nat.Rev.Drug.Discovery 7,591-607.
34. 3 expression with 18F-FRGD2. J. Nucl. Med. 47, 113-121.
35. 18F]Galacto-RGD. PLoS Med. 2, e70.
36. 3 expression in man. Clin. Cancer Res. 12, 3942-3949.
37. Jung, K. H., Lee, K. H., Paik, J. Y., Ko, B. H., Bae, J. S., Lee, B. C., Sung, H. J., Kim, D. H., Choe, Y. S., and Chi, D. Y. (2006) Favorable biokinetic and tumor-targeting properties of 99mTc-labeled glucosamino RGD and effect of paclitaxel therapy. J. Nucl. Med. 47, 2000-2007.